FindTrial
Sign In

A clinical study on Ayurveda intervention along with Standard Care Treatment in mild to moderate patients of COVID-19

A randomised controlled clinical study on Ayurveda intervention (Ayush 64, Sanshamani Vati and Vatashleshma Jwarhar Kwatha) along with Standard Care Treatment in mild to moderate patients of COVID-19

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033651
Enrollment
30
Registered
2021-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Ayush 64 capsule Sanshamani Vati Vatashleshma Jwarhar Kwatha: Ayush 64 capsule 2 Capsule thrice in a day Sanshamani Vati 2 Tablet thrice in a day Vatashleshma Jwarhar Kwatha, 20

Sponsors

Dr SR Rajasthan Ayurved University Jodhpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All hospitalized cases 18-60 years of age, clinically diagnosed with corona virus disease 2019 (Covid19) and who are symptomatic and having Mild to moderate symptoms. 2. Participants who can take medicines orally. 3. Patients taking standard care treatment 4. Patients willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Cases of severe vomiting which would affect oral administration of medicine difficult. 2. Cases of respiratory failure and requiring mechanical ventilation. 3. Patients having Alanine Transaminase (ALT) or Aspartate Transaminase (AST) > 5 times the upper range of normal limits. 4. Patients with COVID-19 in critical condition or ARDS or NIAD 8 â??point ordinal score-2 (Hospitalized, on invasive mechanical Ventilation or extra corporeal membrane oxygenation 5. Combined organ failure requiring ICU monitoring. 6. Patients with uncontrolled Diabetes Mellitus, (HbA1c more than 8.0), Malignant Hypertension (systolic BP more than 180 and diastolic 110), Chronic Renal Failure and those on immunosuppressive medication. 7. Patients with history of malignancy, IHD, CAD, triple vessel disease, history of CABG, Stroke, etc. 8. Any other condition, which as per the investigator would jeopardize the outcome of the trial.

Design outcomes

Primary

MeasureTime frame
1. Clinical cure rate: Time to get a negative status of Covid-19. (defined as viral load of respiratory specimen negative for two consecutive times when tested in an interval of two days) [Time frame 1 month] 2. Duration of fever and each of the respiratory symptoms [Time frame 1 month]. Timepoint: 4weeks—

Secondary

MeasureTime frame
1. No of cases Reporting any ADR/AE 2. Number of patients referred. 3. Number of cases that required invasive or non-invasive oxygen therapy during the intervention. 4. Number of cases that progressed to multi- organ failure while under clinical trial. Timepoint: 1 month—

Countries

India

Contacts

Public ContactDR SANJAY SRIVASTAVA

Dr. S.R. Rajasthan Ayurved University, Jodhpur

vc.dsrrau@gmail.com8800543828

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026